| 1 |
AAV gene therapy for Pendrin mutation-associated sensorineural hearing loss |
| rProtein |
DFNB4/PDS |
SLC26A4 |
Candidate |
ICM Co., Ltd. |
RS-2026-25503251 |
|
| 2 |
Lead optimization for sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism |
| rProtein |
Sarcopenia |
NOTCH1 |
Candidate |
NB Science Co., Ltd. |
RS-2025-25453248 |
|
| 3 |
Non-clinical development of ARBM-101 as an innovative Wilson's disease drug |
| rProtein |
Wilson disease |
ATP7B |
Preclinical |
ARBORMED |
RS-2025-02213496 |
|
| 4 |
Phase 1 clinical development of TU7710, bypassing agent for hemophilia with prolonged half life. |
| rProtein |
Haemophilia A, B |
recombinant coagulation factor VIIa |
Phase 1 |
TiumBio Co., Ltd. |
RS-2023-00282592 |
|
| 5 |
Pre-clinical studies of DMOAD candidate DRT-101 for Osteoarthritis |
| rProtein |
Degenerative arthritis |
bmp7 |
Preclinical |
Darnatein |
RS-2023-00258278 |
|
| 6 |
Pre-clinical study and IND application of PAT101, a tophaceous gout treatment, using SelecAllTM technology |
| rProtein |
Gout |
Uric Acid |
Preclinical |
ProAbTech |
RS-2023-00219125 |
|
| 7 |
Candidate optimization of ARBM-101 as an innovative Wilson's disease drug |
| rProtein |
Wilson disease |
Cu2+ |
Candidate |
ARBORMED |
RS-2023-00218925 |
|
| 8 |
Multi-modal cell-penetrating peptide for diabetic foot ulcer |
| rProtein |
Diabetic foot ulcer |
pre-let7 miRNA |
Preclinical |
StemMeditech Inc. |
RS-2022-00165887 |
|
| 9 |
Lead discovery and development of production process for
sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism |
| rProtein |
Sarcopenia |
NOTCH1 |
Lead |
NUON Bio |
RS-2022-00165803 |
|
| 10 |
Exercise-induced myokine CLCF1, a novel potential treatment for sarcopenia |
| rProtein |
Sarcopenia |
CLCF1 |
Hit |
Korea Research Institute of Bioscience and Biotechnology |
HN22C0330 |
|
| 11 |
Phase 1 clinical trial of recombinant hyaluronidase ALT-BB4 |
| rProtein |
N/A |
Hyaluronidase |
Phase 1 |
Alteogen Inc. |
HN22C0112 |
|
| 12 |
Nonclinical Drug Development of anti-achondroplasia therapy for activated FGFR3 inhibition with NPR-B-Targeting Peptide |
| rProtein |
Achondroplasia |
NPR-B |
Preclinical |
Peptron, Inc |
HN21C1247 |
|
| 13 |
Development of peptide T against sarcopenia in a form of muscle-specific delivered fusion peptides |
| rProtein |
Sarcopenia |
TLQP21 |
Hit |
Asan Medical Center |
HN21C0976 |
|